Interferon-Gamma (Infg) expression as a Biomarker to predict the outcome in patients treated with Nivolumab and Pembrolizumab

Trial Profile

Interferon-Gamma (Infg) expression as a Biomarker to predict the outcome in patients treated with Nivolumab and Pembrolizumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 New trial record
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top